Evotec（1EVT）株式概要エボテックSEは、世界中の製薬・バイオテクノロジー業界の創薬・開発パートナーとして活動しています。 詳細1EVT ファンダメンタル分析スノーフレーク・スコア評価3/6将来の成長3/6過去の実績0/6財務の健全性4/6配当金0/6報酬収益は年間71.18%増加すると予測されています 同業他社や業界と比較して、良好な取引価格 リスク分析Italian市場と比較して、過去 3 か月間の株価の変動が非常に大きいすべてのリスクチェックを見る1EVT Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW476,491 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINRODA476,491 investors already sharing narrativesYour Fair Value€Current Price€3.4579.0% 割安 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-197m960m2016201920222025202620282031Revenue €960.1mEarnings €121.7mAdvancedSet Fair ValueView all narrativesEvotec SE 競合他社Fine Foods & Pharmaceuticals N.T.MSymbol: BIT:FFMarket cap: €202.3mShanghai Obio Technology (Group)Symbol: SHSE:688238Market cap: CN¥4.7bCryoportSymbol: NasdaqCM:CYRXMarket cap: US$772.4mCytek BiosciencesSymbol: NasdaqGS:CTKBMarket cap: US$609.6m価格と性能株価の高値、安値、推移の概要Evotec過去の株価現在の株価€3.4552週高値€7.2252週安値€3.40ベータ1.261ヶ月の変化-0.75%3ヶ月変化-26.65%1年変化-47.08%3年間の変化-83.06%5年間の変化-91.98%IPOからの変化-82.14%最新ニュースReported Earnings • Aug 14Second quarter 2026 earnings released: €0.26 loss per share (vs €0.24 loss in 2Q 2025)Second quarter 2026 results: €0.26 loss per share (further deteriorated from €0.24 loss in 2Q 2025). Revenue: €143.5m (down 16% from 2Q 2025). Net loss: €46.6m (loss widened 7.3% from 2Q 2025). Revenue is forecast to grow 6.0% p.a. on average during the next 3 years, compared to a 9.7% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has fallen by 20% per year but the company’s share price has fallen by 45% per year, which means it is performing significantly worse than earnings.New Risk • Jul 14New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Italian stocks, typically moving 9.3% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. This is currently the only risk that has been identified for the company.お知らせ • Jul 14+ 1 more updateEvotec SE Provides Group Earnings Guidance for the First Half Ended June 30, 2026Evotec SE provided Group earnings guidance for the first half ended June 30, 2026. Based on preliminary figures, the company expects Group revenues for the first half of 2026 of approximately €300.1 million.お知らせ • Jul 01Just – Evotec Biologics Launches J.TRAIN Turnkey Continuous Manufacturing Platform For BiologicsJust – Evotec Biologics expanded its services with J.TRAIN, a new offering that enables biopharmaceutical companies to deploy Evotec's proprietary continuous manufacturing technology directly within their own facilities on a turnkey basis. J.TRAIN brings together prefabricated modular cleanrooms and industry-standard manufacturing equipment with Just – Evotec Biologics' cGMP-compliant process automation, designed to enable significantly faster and more cost-effective deployment than traditional manufacturing expansion. Unveiled in April 2026 at the INTERPHEX conference in New York City, J.TRAIN allows customers and partners to establish high-performance biologics manufacturing capacity on their own premises, effectively embedding advanced manufacturing capabilities directly into their operations. Proprietary automation scripts for continuous process control, as well as digital validation, documentation and training protocols are all designed to significantly streamline implementation and ensure regulatory readiness. J.TRAIN represents a step change in productivity and efficiency compared to conventional fed-batch approaches. It can enable the production of more than 500 kilograms of drug substance from less than 10,000 square feet of cleanroom space, achieving productivity levels more than ten times traditional methods. This efficiency is expected to translate into substantially lower operating costs per unit mass while allowing production scale to be flexibly adjusted through the duration of manufacturing runs rather than the size of the facility. The integrated nature of the J.TRAIN design allows for rapid transitions between products, minimizing downtime and supporting multi-product manufacturing environments. With deployment timelines of approximately 18 months, J.TRAIN offers a significantly faster pathway to capacity expansion compared to traditional biologics manufacturing facilities. This shorter build time positions the solution as a compelling alternative for companies seeking to rapidly increase manufacturing capabilities in response to growing demand.お知らせ • Jun 13Evotec Se Announces Board ChangesEvotec SE announced the results of its Annual General Meeting held on June 11, 2026. Shareholders elected Dieter Weinand and Dr. Wolfgang Hofmann to the Supervisory Board. Following the Annual General Meeting, the Supervisory Board appointed Dieter Weinand as its Chairman, succeeding Prof. Dr. Iris Löw-Friedrich. In addition, shareholders approved the re-election of Dr. Duncan McHale and Wesley Wheeler to the Supervisory Board.Reported Earnings • May 11First quarter 2026 earnings released: €0.69 loss per share (vs €0.18 loss in 1Q 2025)First quarter 2026 results: €0.69 loss per share (further deteriorated from €0.18 loss in 1Q 2025). Revenue: €156.6m (down 22% from 1Q 2025). Net loss: €121.9m (loss widened 286% from 1Q 2025). Revenue is forecast to grow 6.7% p.a. on average during the next 3 years, compared to a 9.5% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has fallen by 18% per year but the company’s share price has fallen by 36% per year, which means it is performing significantly worse than earnings.最新情報をもっと見るRecent updatesReported Earnings • Aug 14Second quarter 2026 earnings released: €0.26 loss per share (vs €0.24 loss in 2Q 2025)Second quarter 2026 results: €0.26 loss per share (further deteriorated from €0.24 loss in 2Q 2025). Revenue: €143.5m (down 16% from 2Q 2025). Net loss: €46.6m (loss widened 7.3% from 2Q 2025). Revenue is forecast to grow 6.0% p.a. on average during the next 3 years, compared to a 9.7% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has fallen by 20% per year but the company’s share price has fallen by 45% per year, which means it is performing significantly worse than earnings.New Risk • Jul 14New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Italian stocks, typically moving 9.3% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. This is currently the only risk that has been identified for the company.お知らせ • Jul 14+ 1 more updateEvotec SE Provides Group Earnings Guidance for the First Half Ended June 30, 2026Evotec SE provided Group earnings guidance for the first half ended June 30, 2026. Based on preliminary figures, the company expects Group revenues for the first half of 2026 of approximately €300.1 million.お知らせ • Jul 01Just – Evotec Biologics Launches J.TRAIN Turnkey Continuous Manufacturing Platform For BiologicsJust – Evotec Biologics expanded its services with J.TRAIN, a new offering that enables biopharmaceutical companies to deploy Evotec's proprietary continuous manufacturing technology directly within their own facilities on a turnkey basis. J.TRAIN brings together prefabricated modular cleanrooms and industry-standard manufacturing equipment with Just – Evotec Biologics' cGMP-compliant process automation, designed to enable significantly faster and more cost-effective deployment than traditional manufacturing expansion. Unveiled in April 2026 at the INTERPHEX conference in New York City, J.TRAIN allows customers and partners to establish high-performance biologics manufacturing capacity on their own premises, effectively embedding advanced manufacturing capabilities directly into their operations. Proprietary automation scripts for continuous process control, as well as digital validation, documentation and training protocols are all designed to significantly streamline implementation and ensure regulatory readiness. J.TRAIN represents a step change in productivity and efficiency compared to conventional fed-batch approaches. It can enable the production of more than 500 kilograms of drug substance from less than 10,000 square feet of cleanroom space, achieving productivity levels more than ten times traditional methods. This efficiency is expected to translate into substantially lower operating costs per unit mass while allowing production scale to be flexibly adjusted through the duration of manufacturing runs rather than the size of the facility. The integrated nature of the J.TRAIN design allows for rapid transitions between products, minimizing downtime and supporting multi-product manufacturing environments. With deployment timelines of approximately 18 months, J.TRAIN offers a significantly faster pathway to capacity expansion compared to traditional biologics manufacturing facilities. This shorter build time positions the solution as a compelling alternative for companies seeking to rapidly increase manufacturing capabilities in response to growing demand.お知らせ • Jun 13Evotec Se Announces Board ChangesEvotec SE announced the results of its Annual General Meeting held on June 11, 2026. Shareholders elected Dieter Weinand and Dr. Wolfgang Hofmann to the Supervisory Board. Following the Annual General Meeting, the Supervisory Board appointed Dieter Weinand as its Chairman, succeeding Prof. Dr. Iris Löw-Friedrich. In addition, shareholders approved the re-election of Dr. Duncan McHale and Wesley Wheeler to the Supervisory Board.Reported Earnings • May 11First quarter 2026 earnings released: €0.69 loss per share (vs €0.18 loss in 1Q 2025)First quarter 2026 results: €0.69 loss per share (further deteriorated from €0.18 loss in 1Q 2025). Revenue: €156.6m (down 22% from 1Q 2025). Net loss: €121.9m (loss widened 286% from 1Q 2025). Revenue is forecast to grow 6.7% p.a. on average during the next 3 years, compared to a 9.5% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has fallen by 18% per year but the company’s share price has fallen by 36% per year, which means it is performing significantly worse than earnings.お知らせ • May 06Evotec SE, Annual General Meeting, Jun 11, 2026Evotec SE, Annual General Meeting, Jun 11, 2026, at 10:00 W. Europe Standard Time.Reported Earnings • Apr 09Full year 2025 earnings released: €0.58 loss per share (vs €1.11 loss in FY 2024)Full year 2025 results: €0.58 loss per share (improved from €1.11 loss in FY 2024). Revenue: €788.4m (down 1.1% from FY 2024). Net loss: €103.5m (loss narrowed 47% from FY 2024). Revenue is forecast to grow 6.3% p.a. on average during the next 3 years, compared to a 9.7% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has fallen by 10% per year but the company’s share price has fallen by 38% per year, which means it is performing significantly worse than earnings.お知らせ • Apr 08Gilead Sciences, Inc. (NasdaqGS:GILD) entered into a definitive agreement to acquire Tubulis GmbH from a group of shareholders for $5 billion.Gilead Sciences, Inc. (NasdaqGS:GILD) entered into a definitive agreement to acquire Tubulis GmbH from a group of shareholders for $5 billion on April 7, 2026. Under the terms of the sale and purchase agreement, Gilead will acquire all of the outstanding equity of Tubulis for $3.15 billion in upfront cash consideration on a cash-free, debt-free basis, subject to customary adjustments, which is payable at closing, and up to $1.85 billion in contingent milestone payments. Evotec announced that it is expected to receive approximately $100 million in upfront consideration upon closing of the sale of Tubulis and is eligible to receive up to approximately $58 million in additional contingent consideration in line with its equity participation and subject to the achievement of specified milestones. Following the close of the transaction, Tubulis will operate as a dedicated ADC research organization within Gilead, with the Munich site serving as a hub for ADC innovation. Gilead plans to finance the transaction with a combination of cash on hand and senior unsecured notes. Closing of the transaction is subject to expiration or termination of certain regulatory filings and other customary conditions. The transaction is expected to close in the second quarter of 2026. Centerview Partners LLC and Allen & Company LLC are acting as financial advisors for Gilead. J.P. Morgan Securities LLC is acting as the exclusive financial advisor for Tubulis. Covington & Burling LLP, Arnold & Porter LLP, and Venable LLP are serving as legal counsel to Gilead. Goodwin Procter LLP and CMS Hasche Sigle are serving as legal counsel to Tubulis.お知らせ • Apr 04Evotec SE Appoints Ashiq H. Khan as EVP Global Head, Chief Commercial OfficerEvotec SE announced the appointment of Dr. Ashiq H. Khan as EVP Global Head, Chief Commercial Officer. Dr. Khan brings to Evotec over 15 years of international leadership experience in biotech, CRO and AI-driven platform businesses, with a distinguished track record of managing diverse transcontinental teams and closing more than $7 billion in high-value standalone, integrated, and collaboration agreements across the U.S., EU and APAC markets. In his role, Dr. Khan will spearhead the build-out of a globally integrated, fit-for-purpose commercial organization fully aligned with Evotec's scientific leadership and platform capabilities to deliver enhanced customer value and drive more robust, sustainable growth. Dr. Khan most recently served as Chief Business Officer at Iktos. Prior to that, he held leadership roles at Proteros and Schrödinger. He holds a Ph.D. in Neurobiology from the University of Cologne and business degrees from the Wharton Business School and INSEAD.お知らせ • Mar 29+ 2 more updatesEvotec SE to Report Q2, 2026 Results on Aug 13, 2026Evotec SE announced that they will report Q2, 2026 results on Aug 13, 2026お知らせ • Mar 11Evotec SE to Report Q4, 2025 Final Results on Apr 08, 2026Evotec SE announced that they will report Q4, 2025 final results at 12:00 PM, Central European Standard Time on Apr 08, 2026お知らせ • Jan 07Amgen Inc. (NasdaqGS:AMGN) acquired Dark Blue Therapeutics Ltd from Oxford Science Enterprises, Bristol-Myers Squibb Company (NYSE:BMY) and Evotec SE (XTRA:EVT) in a transaction valued at $840 million.Amgen Inc. (NasdaqGS:AMGN) acquired Dark Blue Therapeutics Ltd from Oxford Science Enterprises, Bristol-Myers Squibb Company (NYSE:BMY) and Evotec SE (XTRA:EVT) in a transaction valued at $840 million on December 30, 2025. Under the terms of the agreement, Dark Blue Therapeutics’ board has resigned, and Edwin Moses is no longer directly involved in the company. Its 18-person team and research operations will be integrated into Amgen’s global R&D organization. Merrill Lynch International acted as financial advisor for Dark Blue Therapeutics Ltd. Goodwin Procter Llp acted as legal advisor for Dark Blue Therapeutics Ltd. Amgen Inc. (NasdaqGS:AMGN) completed the acquisition of Dark Blue Therapeutics Ltd from Oxford Science Enterprises, Bristol-Myers Squibb Company (NYSE:BMY) and Evotec SE (XTRA:EVT) on December 30, 2025.お知らせ • Jan 02Evotec SE Announces Executive ChangesEvotec SE announced the appointment of Dr. Sarah Fakih as Executive Vice President, Head of Global Communications and Investor Relations. In this strategic role, Dr. Fakih will lead Evotec's newly integrated Global Communications and Investor Relations function. Reporting directly to CEO Dr. Christian Wojczewski, she will bring together both teams to strengthen alignment, clarity and engagement across stakeholders. Dr. Fakih brings more than 15 years of experience in life sciences, with a strong leadership track record in capital markets strategy and corporate messaging. She has held senior roles at U.S. listed companies, including QIAGEN, MorphoSys, and most recently at CureVac. She holds a PhD in Chemistry. The appointment follows the departure of Volker Braun, who successfully led Evotec's Investor Relations and ESG function over the past five years.お知らせ • Nov 08Evotec SE (XTRA:EVT) announces an Equity Buyback for 290,000 shares, for €3 million.Evotec SE (XTRA:EVT) announces a share repurchase program. Under the program, the company will repurchase up to 290,000 shares for €3 million. The purchased shares will be converted to American Depositary Shares (ADS) and ADS will be used exclusively to fulfil corresponding obligations under an employee share program and shall be issued only to individuals who are or were employed by the company or an affiliated company. The program will be valid till December 17, 2025.Reported Earnings • Nov 06Third quarter 2025 earnings released: €0.24 loss per share (vs €0.22 loss in 3Q 2024)Third quarter 2025 results: €0.24 loss per share (further deteriorated from €0.22 loss in 3Q 2024). Revenue: €163.9m (down 11% from 3Q 2024). Net loss: €43.1m (loss widened 8.7% from 3Q 2024). Revenue is forecast to grow 9.0% p.a. on average during the next 3 years, compared to a 9.6% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has fallen by 10% per year but the company’s share price has fallen by 32% per year, which means it is performing significantly worse than earnings.Reported Earnings • Aug 14Second quarter 2025 earnings released: €0.24 loss per share (vs €0.54 loss in 2Q 2024)Second quarter 2025 results: €0.24 loss per share (improved from €0.54 loss in 2Q 2024). Revenue: €171.2m (down 6.0% from 2Q 2024). Net loss: €43.5m (loss narrowed 54% from 2Q 2024). Revenue is forecast to grow 9.0% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has fallen by 24% per year but the company’s share price has fallen by 37% per year, which means it is performing significantly worse than earnings.お知らせ • Jul 30Sandoz Group AG (SWX:SDZ) signed a non-binding term sheet to acquire Just-evotec Biologics Eu from Evotec SE (XTRA:EVT) for $300 million.Sandoz Group AG (SWX:SDZ) signed a non-binding term sheet to acquire Just-evotec Biologics Eu from Evotec SE (XTRA:EVT) for $300 million on July 30, 2025. The deal terms include the purchase price of the site for around $300 million in cash, and in addition will include further technology related consideration, future development revenues, milestones and product royalties. Upon completion of the proposed transaction, Just-evotec Biologics employees would transfer with the acquired entity and would become part of the Sandoz Group. Closing of the planned transaction remains subject to completion of the relevant information and consultation processes with employees and their representatives, final contractual agreements and to meeting regulatory requirements, expected in the fourth quarter.お知らせ • Jul 22Evotec SE Updates Earnings Guidance for the Fiscal Year 2025Evotec SE updated earnings guidance for the fiscal year 2025. For the year, the Company expects Group revenues in the range of EUR 760 million – EUR 800 million (previously: EUR 840 million – EUR 880 million). The primary reasons for the refined guidance are a change in the revenue mix and significant cost savings in excess of initial targets set during the Priority Reset. Technology licensing – a key pillar of Evotec’s strategic repositioning – is expected to make a stronger contribution. At the same time, the Shared R&D base business is expected to continue to operate in a challenging market environment in the second half of 2025. Group revenues were below expectations in H1 2025, while adjusted EBITDA was broadly in line with expectations. Actions are underway to transform the business towards sustainable profitable growth.New Risk • Jul 04New major risk - Revenue and earnings growthEarnings have declined by 55% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Earnings have declined by 55% per year over the past 5 years.お知らせ • Jun 04Evotec SE Approves Board AppointmentsEvotec SE approved the two new Management Board members Aurélie Dalbiez (Chief People Officer) and Paul Hitchin (Chief Financial Officer), introduced themselves to the shareholders at its AGM held on June 3, 2025.Buy Or Sell Opportunity • May 23Now 30% overvaluedOver the last 90 days, the stock has fallen 3.0% to €8.24. The fair value is estimated to be €6.33, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 5.1% over the last 3 years. Meanwhile, the company became loss making. Revenue is forecast to grow by 24% in 2 years. Earnings are forecast to grow by 96% in the next 2 years.お知らせ • Apr 28Evotec SE, Annual General Meeting, Jun 03, 2025Evotec SE, Annual General Meeting, Jun 03, 2025, at 10:00 W. Europe Standard Time.Breakeven Date Change • Apr 17Forecast breakeven date pushed back to 2027The 8 analysts covering Evotec previously expected the company to break even in 2026. New consensus forecast suggests the company will make a profit of €48.4m in 2027. Average annual earnings growth of 73% is required to achieve expected profit on schedule.お知らせ • Apr 17Evotec SE Provides Earnings Guidance for the Full Year of 2025 and Outlook for the Year 2028Evotec SE provided earnings guidance for the full year of 2025 and outlook for the year 2028. For the year 2025, the group revenues expected in the range of €840 million to €880 million (2024: €797.0 million). For the outlook for 2028, the group revenues CAGR 2024-2028 targeted to be in a range of 8% to 12%.株主還元1EVTIT Life SciencesIT 市場7D-1.0%0.5%-0.1%1Y-47.1%2.2%21.8%株主還元を見る業界別リターン: 1EVT過去 1 年間で2.2 % の収益を上げたItalian Life Sciences業界を下回りました。リターン対市場: 1EVTは、過去 1 年間で21.8 % のリターンを上げたItalian市場を下回りました。価格変動Is 1EVT's price volatile compared to industry and market?1EVT volatility1EVT Average Weekly Movement9.0%Life Sciences Industry Average Movement5.8%Market Average Movement4.4%10% most volatile stocks in IT Market8.1%10% least volatile stocks in IT Market2.8%安定した株価: 1EVTの株価は、 Italian市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 1EVTの weekly volatility ( 9% ) は過去 1 年間安定していますが、依然としてItalianの株式の 75% よりも高くなっています。会社概要設立従業員CEO（最高経営責任者ウェブサイト19934,461Christian Wojczewskiwww.evotec.comエボテックSEは、世界中の製薬・バイオテクノロジー業界の創薬・開発パートナーとして事業を展開している。Shared R&D と Just Evotec Biologics の2つのセグメントで事業を展開している。同社は、がん、自己免疫疾患、がん、糖尿病、心不全、線維症、免疫学、疼痛・炎症、感染症、腎臓、肝臓、希少疾患、呼吸器、線維症、代謝性疾患、中枢神経系（CNS）および心臓代謝疾患、動物および女性の健康など、さまざまな治療分野における医薬品を開発している。同社は、マサチューセッツ州ブリガムジェネラル病院およびジョスリン糖尿病センター、BMS社抗ウイルス薬、ノボノルディスク社細胞治療薬、オックスフォード大学、ドイツがん研究センター、ハンブルグ大学病院、トロント大学、ハーバード大学、イェール大学、ジョンズ・ホプキンス大学、オスペダーレ・サン・ラファエレ（OSR）、シンガポール国立大学と、心代謝性疾患に関する共同研究契約を結んでいる。また、LAB282、LAB150、beLAB2122、beLAB1407、LAB eN²、Danube Labs、VC Amplitude Ventures、LaB eN2、65LAB、バイエル、ノボノルディスク、イーライリリー、ノバルティスの腎臓病関連企業、サンド、患者支援団体、ベンチャーキャピタルと提携しているほか、ブリストル・マイヤーズ・スクイブ社と戦略的研究提携契約を結び、アンメット・メディカル・ニーズに対する分子接着剤ベースのパイプラインを構築している。同社は以前Evotec AGとして知られていたが、2019年4月にEvotec SEに社名を変更した。Evotec SEは1993年に法人化され、ドイツのハンブルグに本社を置いている。もっと見るEvotec SE 基礎のまとめEvotec の収益と売上を時価総額と比較するとどうか。1EVT 基礎統計学時価総額€612.52m収益（TTM）-€197.05m売上高(TTM)€717.28m0.9xP/Sレシオ-3.1xPER（株価収益率1EVT は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計1EVT 損益計算書（TTM）収益€717.28m売上原価€656.57m売上総利益€60.71mその他の費用€257.76m収益-€197.05m直近の収益報告Jun 30, 2026次回決算日Nov 05, 2026一株当たり利益（EPS）-1.11グロス・マージン8.46%純利益率-27.47%有利子負債／自己資本比率47.7%1EVT の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/08/16 19:52終値2026/08/14 00:00収益2026/06/30年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Evotec SE 10 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。24 アナリスト機関Christian EhmannBerenbergMichael RyskinBofA Global ResearchPeter VerdultCitigroup Inc21 その他のアナリストを表示
Reported Earnings • Aug 14Second quarter 2026 earnings released: €0.26 loss per share (vs €0.24 loss in 2Q 2025)Second quarter 2026 results: €0.26 loss per share (further deteriorated from €0.24 loss in 2Q 2025). Revenue: €143.5m (down 16% from 2Q 2025). Net loss: €46.6m (loss widened 7.3% from 2Q 2025). Revenue is forecast to grow 6.0% p.a. on average during the next 3 years, compared to a 9.7% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has fallen by 20% per year but the company’s share price has fallen by 45% per year, which means it is performing significantly worse than earnings.
New Risk • Jul 14New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Italian stocks, typically moving 9.3% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. This is currently the only risk that has been identified for the company.
お知らせ • Jul 14+ 1 more updateEvotec SE Provides Group Earnings Guidance for the First Half Ended June 30, 2026Evotec SE provided Group earnings guidance for the first half ended June 30, 2026. Based on preliminary figures, the company expects Group revenues for the first half of 2026 of approximately €300.1 million.
お知らせ • Jul 01Just – Evotec Biologics Launches J.TRAIN Turnkey Continuous Manufacturing Platform For BiologicsJust – Evotec Biologics expanded its services with J.TRAIN, a new offering that enables biopharmaceutical companies to deploy Evotec's proprietary continuous manufacturing technology directly within their own facilities on a turnkey basis. J.TRAIN brings together prefabricated modular cleanrooms and industry-standard manufacturing equipment with Just – Evotec Biologics' cGMP-compliant process automation, designed to enable significantly faster and more cost-effective deployment than traditional manufacturing expansion. Unveiled in April 2026 at the INTERPHEX conference in New York City, J.TRAIN allows customers and partners to establish high-performance biologics manufacturing capacity on their own premises, effectively embedding advanced manufacturing capabilities directly into their operations. Proprietary automation scripts for continuous process control, as well as digital validation, documentation and training protocols are all designed to significantly streamline implementation and ensure regulatory readiness. J.TRAIN represents a step change in productivity and efficiency compared to conventional fed-batch approaches. It can enable the production of more than 500 kilograms of drug substance from less than 10,000 square feet of cleanroom space, achieving productivity levels more than ten times traditional methods. This efficiency is expected to translate into substantially lower operating costs per unit mass while allowing production scale to be flexibly adjusted through the duration of manufacturing runs rather than the size of the facility. The integrated nature of the J.TRAIN design allows for rapid transitions between products, minimizing downtime and supporting multi-product manufacturing environments. With deployment timelines of approximately 18 months, J.TRAIN offers a significantly faster pathway to capacity expansion compared to traditional biologics manufacturing facilities. This shorter build time positions the solution as a compelling alternative for companies seeking to rapidly increase manufacturing capabilities in response to growing demand.
お知らせ • Jun 13Evotec Se Announces Board ChangesEvotec SE announced the results of its Annual General Meeting held on June 11, 2026. Shareholders elected Dieter Weinand and Dr. Wolfgang Hofmann to the Supervisory Board. Following the Annual General Meeting, the Supervisory Board appointed Dieter Weinand as its Chairman, succeeding Prof. Dr. Iris Löw-Friedrich. In addition, shareholders approved the re-election of Dr. Duncan McHale and Wesley Wheeler to the Supervisory Board.
Reported Earnings • May 11First quarter 2026 earnings released: €0.69 loss per share (vs €0.18 loss in 1Q 2025)First quarter 2026 results: €0.69 loss per share (further deteriorated from €0.18 loss in 1Q 2025). Revenue: €156.6m (down 22% from 1Q 2025). Net loss: €121.9m (loss widened 286% from 1Q 2025). Revenue is forecast to grow 6.7% p.a. on average during the next 3 years, compared to a 9.5% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has fallen by 18% per year but the company’s share price has fallen by 36% per year, which means it is performing significantly worse than earnings.
Reported Earnings • Aug 14Second quarter 2026 earnings released: €0.26 loss per share (vs €0.24 loss in 2Q 2025)Second quarter 2026 results: €0.26 loss per share (further deteriorated from €0.24 loss in 2Q 2025). Revenue: €143.5m (down 16% from 2Q 2025). Net loss: €46.6m (loss widened 7.3% from 2Q 2025). Revenue is forecast to grow 6.0% p.a. on average during the next 3 years, compared to a 9.7% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has fallen by 20% per year but the company’s share price has fallen by 45% per year, which means it is performing significantly worse than earnings.
New Risk • Jul 14New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Italian stocks, typically moving 9.3% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. This is currently the only risk that has been identified for the company.
お知らせ • Jul 14+ 1 more updateEvotec SE Provides Group Earnings Guidance for the First Half Ended June 30, 2026Evotec SE provided Group earnings guidance for the first half ended June 30, 2026. Based on preliminary figures, the company expects Group revenues for the first half of 2026 of approximately €300.1 million.
お知らせ • Jul 01Just – Evotec Biologics Launches J.TRAIN Turnkey Continuous Manufacturing Platform For BiologicsJust – Evotec Biologics expanded its services with J.TRAIN, a new offering that enables biopharmaceutical companies to deploy Evotec's proprietary continuous manufacturing technology directly within their own facilities on a turnkey basis. J.TRAIN brings together prefabricated modular cleanrooms and industry-standard manufacturing equipment with Just – Evotec Biologics' cGMP-compliant process automation, designed to enable significantly faster and more cost-effective deployment than traditional manufacturing expansion. Unveiled in April 2026 at the INTERPHEX conference in New York City, J.TRAIN allows customers and partners to establish high-performance biologics manufacturing capacity on their own premises, effectively embedding advanced manufacturing capabilities directly into their operations. Proprietary automation scripts for continuous process control, as well as digital validation, documentation and training protocols are all designed to significantly streamline implementation and ensure regulatory readiness. J.TRAIN represents a step change in productivity and efficiency compared to conventional fed-batch approaches. It can enable the production of more than 500 kilograms of drug substance from less than 10,000 square feet of cleanroom space, achieving productivity levels more than ten times traditional methods. This efficiency is expected to translate into substantially lower operating costs per unit mass while allowing production scale to be flexibly adjusted through the duration of manufacturing runs rather than the size of the facility. The integrated nature of the J.TRAIN design allows for rapid transitions between products, minimizing downtime and supporting multi-product manufacturing environments. With deployment timelines of approximately 18 months, J.TRAIN offers a significantly faster pathway to capacity expansion compared to traditional biologics manufacturing facilities. This shorter build time positions the solution as a compelling alternative for companies seeking to rapidly increase manufacturing capabilities in response to growing demand.
お知らせ • Jun 13Evotec Se Announces Board ChangesEvotec SE announced the results of its Annual General Meeting held on June 11, 2026. Shareholders elected Dieter Weinand and Dr. Wolfgang Hofmann to the Supervisory Board. Following the Annual General Meeting, the Supervisory Board appointed Dieter Weinand as its Chairman, succeeding Prof. Dr. Iris Löw-Friedrich. In addition, shareholders approved the re-election of Dr. Duncan McHale and Wesley Wheeler to the Supervisory Board.
Reported Earnings • May 11First quarter 2026 earnings released: €0.69 loss per share (vs €0.18 loss in 1Q 2025)First quarter 2026 results: €0.69 loss per share (further deteriorated from €0.18 loss in 1Q 2025). Revenue: €156.6m (down 22% from 1Q 2025). Net loss: €121.9m (loss widened 286% from 1Q 2025). Revenue is forecast to grow 6.7% p.a. on average during the next 3 years, compared to a 9.5% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has fallen by 18% per year but the company’s share price has fallen by 36% per year, which means it is performing significantly worse than earnings.
お知らせ • May 06Evotec SE, Annual General Meeting, Jun 11, 2026Evotec SE, Annual General Meeting, Jun 11, 2026, at 10:00 W. Europe Standard Time.
Reported Earnings • Apr 09Full year 2025 earnings released: €0.58 loss per share (vs €1.11 loss in FY 2024)Full year 2025 results: €0.58 loss per share (improved from €1.11 loss in FY 2024). Revenue: €788.4m (down 1.1% from FY 2024). Net loss: €103.5m (loss narrowed 47% from FY 2024). Revenue is forecast to grow 6.3% p.a. on average during the next 3 years, compared to a 9.7% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has fallen by 10% per year but the company’s share price has fallen by 38% per year, which means it is performing significantly worse than earnings.
お知らせ • Apr 08Gilead Sciences, Inc. (NasdaqGS:GILD) entered into a definitive agreement to acquire Tubulis GmbH from a group of shareholders for $5 billion.Gilead Sciences, Inc. (NasdaqGS:GILD) entered into a definitive agreement to acquire Tubulis GmbH from a group of shareholders for $5 billion on April 7, 2026. Under the terms of the sale and purchase agreement, Gilead will acquire all of the outstanding equity of Tubulis for $3.15 billion in upfront cash consideration on a cash-free, debt-free basis, subject to customary adjustments, which is payable at closing, and up to $1.85 billion in contingent milestone payments. Evotec announced that it is expected to receive approximately $100 million in upfront consideration upon closing of the sale of Tubulis and is eligible to receive up to approximately $58 million in additional contingent consideration in line with its equity participation and subject to the achievement of specified milestones. Following the close of the transaction, Tubulis will operate as a dedicated ADC research organization within Gilead, with the Munich site serving as a hub for ADC innovation. Gilead plans to finance the transaction with a combination of cash on hand and senior unsecured notes. Closing of the transaction is subject to expiration or termination of certain regulatory filings and other customary conditions. The transaction is expected to close in the second quarter of 2026. Centerview Partners LLC and Allen & Company LLC are acting as financial advisors for Gilead. J.P. Morgan Securities LLC is acting as the exclusive financial advisor for Tubulis. Covington & Burling LLP, Arnold & Porter LLP, and Venable LLP are serving as legal counsel to Gilead. Goodwin Procter LLP and CMS Hasche Sigle are serving as legal counsel to Tubulis.
お知らせ • Apr 04Evotec SE Appoints Ashiq H. Khan as EVP Global Head, Chief Commercial OfficerEvotec SE announced the appointment of Dr. Ashiq H. Khan as EVP Global Head, Chief Commercial Officer. Dr. Khan brings to Evotec over 15 years of international leadership experience in biotech, CRO and AI-driven platform businesses, with a distinguished track record of managing diverse transcontinental teams and closing more than $7 billion in high-value standalone, integrated, and collaboration agreements across the U.S., EU and APAC markets. In his role, Dr. Khan will spearhead the build-out of a globally integrated, fit-for-purpose commercial organization fully aligned with Evotec's scientific leadership and platform capabilities to deliver enhanced customer value and drive more robust, sustainable growth. Dr. Khan most recently served as Chief Business Officer at Iktos. Prior to that, he held leadership roles at Proteros and Schrödinger. He holds a Ph.D. in Neurobiology from the University of Cologne and business degrees from the Wharton Business School and INSEAD.
お知らせ • Mar 29+ 2 more updatesEvotec SE to Report Q2, 2026 Results on Aug 13, 2026Evotec SE announced that they will report Q2, 2026 results on Aug 13, 2026
お知らせ • Mar 11Evotec SE to Report Q4, 2025 Final Results on Apr 08, 2026Evotec SE announced that they will report Q4, 2025 final results at 12:00 PM, Central European Standard Time on Apr 08, 2026
お知らせ • Jan 07Amgen Inc. (NasdaqGS:AMGN) acquired Dark Blue Therapeutics Ltd from Oxford Science Enterprises, Bristol-Myers Squibb Company (NYSE:BMY) and Evotec SE (XTRA:EVT) in a transaction valued at $840 million.Amgen Inc. (NasdaqGS:AMGN) acquired Dark Blue Therapeutics Ltd from Oxford Science Enterprises, Bristol-Myers Squibb Company (NYSE:BMY) and Evotec SE (XTRA:EVT) in a transaction valued at $840 million on December 30, 2025. Under the terms of the agreement, Dark Blue Therapeutics’ board has resigned, and Edwin Moses is no longer directly involved in the company. Its 18-person team and research operations will be integrated into Amgen’s global R&D organization. Merrill Lynch International acted as financial advisor for Dark Blue Therapeutics Ltd. Goodwin Procter Llp acted as legal advisor for Dark Blue Therapeutics Ltd. Amgen Inc. (NasdaqGS:AMGN) completed the acquisition of Dark Blue Therapeutics Ltd from Oxford Science Enterprises, Bristol-Myers Squibb Company (NYSE:BMY) and Evotec SE (XTRA:EVT) on December 30, 2025.
お知らせ • Jan 02Evotec SE Announces Executive ChangesEvotec SE announced the appointment of Dr. Sarah Fakih as Executive Vice President, Head of Global Communications and Investor Relations. In this strategic role, Dr. Fakih will lead Evotec's newly integrated Global Communications and Investor Relations function. Reporting directly to CEO Dr. Christian Wojczewski, she will bring together both teams to strengthen alignment, clarity and engagement across stakeholders. Dr. Fakih brings more than 15 years of experience in life sciences, with a strong leadership track record in capital markets strategy and corporate messaging. She has held senior roles at U.S. listed companies, including QIAGEN, MorphoSys, and most recently at CureVac. She holds a PhD in Chemistry. The appointment follows the departure of Volker Braun, who successfully led Evotec's Investor Relations and ESG function over the past five years.
お知らせ • Nov 08Evotec SE (XTRA:EVT) announces an Equity Buyback for 290,000 shares, for €3 million.Evotec SE (XTRA:EVT) announces a share repurchase program. Under the program, the company will repurchase up to 290,000 shares for €3 million. The purchased shares will be converted to American Depositary Shares (ADS) and ADS will be used exclusively to fulfil corresponding obligations under an employee share program and shall be issued only to individuals who are or were employed by the company or an affiliated company. The program will be valid till December 17, 2025.
Reported Earnings • Nov 06Third quarter 2025 earnings released: €0.24 loss per share (vs €0.22 loss in 3Q 2024)Third quarter 2025 results: €0.24 loss per share (further deteriorated from €0.22 loss in 3Q 2024). Revenue: €163.9m (down 11% from 3Q 2024). Net loss: €43.1m (loss widened 8.7% from 3Q 2024). Revenue is forecast to grow 9.0% p.a. on average during the next 3 years, compared to a 9.6% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has fallen by 10% per year but the company’s share price has fallen by 32% per year, which means it is performing significantly worse than earnings.
Reported Earnings • Aug 14Second quarter 2025 earnings released: €0.24 loss per share (vs €0.54 loss in 2Q 2024)Second quarter 2025 results: €0.24 loss per share (improved from €0.54 loss in 2Q 2024). Revenue: €171.2m (down 6.0% from 2Q 2024). Net loss: €43.5m (loss narrowed 54% from 2Q 2024). Revenue is forecast to grow 9.0% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has fallen by 24% per year but the company’s share price has fallen by 37% per year, which means it is performing significantly worse than earnings.
お知らせ • Jul 30Sandoz Group AG (SWX:SDZ) signed a non-binding term sheet to acquire Just-evotec Biologics Eu from Evotec SE (XTRA:EVT) for $300 million.Sandoz Group AG (SWX:SDZ) signed a non-binding term sheet to acquire Just-evotec Biologics Eu from Evotec SE (XTRA:EVT) for $300 million on July 30, 2025. The deal terms include the purchase price of the site for around $300 million in cash, and in addition will include further technology related consideration, future development revenues, milestones and product royalties. Upon completion of the proposed transaction, Just-evotec Biologics employees would transfer with the acquired entity and would become part of the Sandoz Group. Closing of the planned transaction remains subject to completion of the relevant information and consultation processes with employees and their representatives, final contractual agreements and to meeting regulatory requirements, expected in the fourth quarter.
お知らせ • Jul 22Evotec SE Updates Earnings Guidance for the Fiscal Year 2025Evotec SE updated earnings guidance for the fiscal year 2025. For the year, the Company expects Group revenues in the range of EUR 760 million – EUR 800 million (previously: EUR 840 million – EUR 880 million). The primary reasons for the refined guidance are a change in the revenue mix and significant cost savings in excess of initial targets set during the Priority Reset. Technology licensing – a key pillar of Evotec’s strategic repositioning – is expected to make a stronger contribution. At the same time, the Shared R&D base business is expected to continue to operate in a challenging market environment in the second half of 2025. Group revenues were below expectations in H1 2025, while adjusted EBITDA was broadly in line with expectations. Actions are underway to transform the business towards sustainable profitable growth.
New Risk • Jul 04New major risk - Revenue and earnings growthEarnings have declined by 55% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Earnings have declined by 55% per year over the past 5 years.
お知らせ • Jun 04Evotec SE Approves Board AppointmentsEvotec SE approved the two new Management Board members Aurélie Dalbiez (Chief People Officer) and Paul Hitchin (Chief Financial Officer), introduced themselves to the shareholders at its AGM held on June 3, 2025.
Buy Or Sell Opportunity • May 23Now 30% overvaluedOver the last 90 days, the stock has fallen 3.0% to €8.24. The fair value is estimated to be €6.33, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 5.1% over the last 3 years. Meanwhile, the company became loss making. Revenue is forecast to grow by 24% in 2 years. Earnings are forecast to grow by 96% in the next 2 years.
お知らせ • Apr 28Evotec SE, Annual General Meeting, Jun 03, 2025Evotec SE, Annual General Meeting, Jun 03, 2025, at 10:00 W. Europe Standard Time.
Breakeven Date Change • Apr 17Forecast breakeven date pushed back to 2027The 8 analysts covering Evotec previously expected the company to break even in 2026. New consensus forecast suggests the company will make a profit of €48.4m in 2027. Average annual earnings growth of 73% is required to achieve expected profit on schedule.
お知らせ • Apr 17Evotec SE Provides Earnings Guidance for the Full Year of 2025 and Outlook for the Year 2028Evotec SE provided earnings guidance for the full year of 2025 and outlook for the year 2028. For the year 2025, the group revenues expected in the range of €840 million to €880 million (2024: €797.0 million). For the outlook for 2028, the group revenues CAGR 2024-2028 targeted to be in a range of 8% to 12%.
